Applied Biocode to Submit Gastrointestinal Pathogen Panel to FDA in Bid to Displace Luminex

Apr 20, 2017

Premium

NEW YORK (GenomeWeb) – Applied Biocode intends to have a panel for identifying 18 different gastrointestinal pathogens on the clinical market by the end of the year.

CEO Winston Ho said that the Santa Fe Springs, California-based molecular diagnostics company will soon commence clinical trials for the assay, called the Gastrointestinal Pathogen Panel, which runs on its barcoded magnetic bead-based multiplex BioCode MDx 3000 system, at five sites in the US.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Main menu